Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 47Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 31Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 22Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Carcinoma, Renal Cell 15Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

Doxorubicin 6Specimen Handling 5Radiotherapy 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3pembrolizumab 2liposomal doxorubicin 2eribulin 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1rucaparib 1ribociclib 1regorafenib 1peposertib 1pazopanib 1olaratumab 1olaparib 1lenvatinib 1futibatinib 1durvalumab 1dinutuximab 1cemiplimab 1cediranib 1cabozantinib 1avelumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leiomyosarcoma × Biopsy × 1 year × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡